Patents by Inventor Guido Tarone

Guido Tarone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant melusin fusion protein as pharmacological agent in the treatment of heart pathologies
    Patent number: 8658598
    Abstract: A recombinant melusin fusion protein having an improved stability and a capability to reach intracellular compartments as compared to recombinant melusin in vivo, wherein said protein comprises i) a human melusin protein having the amino acid sequence as defined in SEQ ID No.:1, or a homologue thereof having at least 60%, preferably at least 80%, more preferably at least 90% sequence identity to SEQ ID No.:1 and having the function of native melusin protein or a human melusin portion derived from SEQ ID No.:1 or homologue thereof having at least 60%, preferably at least 80%, more preferably at least 90% sequence identity of the melusin portion derived from SEQ ID No.:1 and having the function of native melusin protein and ii) a cell penetrating polypeptide.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: February 25, 2014
    Assignee: Target Heart Biotec S.R.L.
    Inventors: Féderica Accornero, Mara Brancaccio, Guido Tarone, Giuseppe Lembo, Daniela Carnevale
  • RECOMBINANT MELUSIN FUSION PROTEIN AS PHARMACOLOGICAL AGENT IN THE TREATMENT OF HEART PATHOLOGIES AND COMPOSITIONS THEREOF
    Publication number: 20120010386
    Abstract: A recombinant melusin fusion protein having an improved stability and a capability to reach intracellular compartments as compared to recombinant melusin in vivo, wherein said protein comprises i) a human melusin protein having the amino acid sequence as defined in SEQ ID No.:1, or a homologue thereof having at least 60%, preferably at least 80%, more preferably at least 90% sequence identity to SEQ ID No.:1 and having the function of native melusin protein or a human melusin portion derived from SEQ ID No.:1 or homologue thereof having at least 60%, preferably at least 80%, more preferably at least 90% sequence identity of the melusin portion derived from SEQ ID No.:1 and having the function of native melusin protein and ii) a cell penetrating polypeptide.
    Type: Application
    Filed: May 12, 2011
    Publication date: January 12, 2012
    Applicant: Target Heart Biotec S.r.l.
    Inventors: Federica Accornero, Mara Brancaccio, Guido Tarone, Giuseppe Lembo, Daniela Carnevale
  • Melusin a muscle specific protein, as a drug target for prevention and treatment of heart failure
    Patent number: 7531714
    Abstract: The present invention concerns non-human transgenic animals as model study for human pathologies, being transgenic for having altered melusin expression. The non-human transgenic animals are to be used as models to study heart pathologies and provide therapies thereof, wherein the heart pathologies are heart failure, and in particular diluted cardiomyopathy.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: May 12, 2009
    Assignee: Universita' Degli Studi de Torino
    Inventors: Mara Brancaccio, Lorenzo Silengo, Fiorella Altruda, Giuseppe Lembo, Luigi Fratta, Guido Tarone
  • Melusin a muscle specific protein, as a drug target for prevention and treatment of heart failure
    Publication number: 20060059577
    Abstract: The present invention concerns non-human transgenic animals as model study for human pathologies, being transgenic for having altered melusin expression. The non-human transgenic animals are to be used as models to study heart pathologies and provide therapies thereof, wherein the heart pathologies are heart failure, and in particular diluted cardiomyopathy.
    Type: Application
    Filed: December 19, 2002
    Publication date: March 16, 2006
    Inventors: Mara Brancaccio, Lorenzo Silengo, Fiorella Altruda, Giuseppe Lembo, Luigi Fratta, Guido Tarone
  • Method for detection of fibronectin receptor ligands
    Patent number: 5591592
    Abstract: The present invention provides a substantially pure integrin characterized in that it consists of an .alpha..sub.v and a .beta..sub.1 subunit. The receptor binds to fibronectin and GRGDSPK but does not bind to vitronectin. The .alpha..sub.v .beta..sub.1 receptor can be used to determine the presence of ligands for the receptor.
    Type: Grant
    Filed: July 22, 1994
    Date of Patent: January 7, 1997
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Erkki I. Ruoslahti, Guido Tarone, Filippo G. Giancotti, Bruce E. Vogel
  • Fibronectin receptor
    Patent number: 5169930
    Abstract: The present invention provides a substantially pure integrin-type receptor characterized in that it consists of an .alpha..sub.v and a .beta..sub.1 subunit. The .alpha..sub.v .beta..sub.1 integrin binds to fibronectin and GRGDSPK but does not bind to vitronectin. The .alpha..sub.v .beta..sub.1 integrin can be used to determine the presence of a .alpha..sub.v .beta..sub.1 ligand and to develop adhesion peptides specific for the various integrins. The presence of the .alpha..sub.v .beta..sub.1 integrin can be used to assess ability of cells to adhere to fibronectin.
    Type: Grant
    Filed: January 5, 1990
    Date of Patent: December 8, 1992
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Erkki I. Ruoslahti, Guido Tarone, Filippo G. Giancotti, Bruce E. Vogel